ED seizes properties worth 8 crore in drug export case

Hyderabad:  The Enforcement Directorate Hyderabad unit has provisionally attached 22 immovable and eight movable properties worth 8 crore under the Prevention of Money Laundering Act in a case involving illegal export of psychotropic substances.

The investigation began after Narcotics Control Bureau (NCB), Hyderabad sub-zonal unit, filed an FIR in May 2022 against Ashish Jain and his family members, based on their involvement in an illegal internet pharmacy operation.
The NCB alleged that Ashish Jain was running a business from JR Infinity Private Limited, exporting psychotropic substances such as Alprazolam, Zolpidem, Lorazepam, Clonazepam, Hydrocodone, and Oxycodone under the guise of providing telemarketing and search engine optimisation services. During searches at the accused’s premises, the NCB seized foreign and Indian currency totaling 3.7 crore and found incriminating evidence regarding the illegal export of drugs. Further probe by ED revealed that Ashish Jain had set up JR Infinity to illegally export psychotropic substances like Alprazolam, Tramadol, and Diazepam to overseas customers, violating the NDPS Act, and generating proceeds of crime.

The ED’s inquiry also uncovered that prior to the company’s formation, Aashish Jain and his family had received over 4.5 crore in foreign remittances into their personal accounts without any legitimate business activities. The total proceeds of crime identified in this case amounted to 12.7 crore.

These illicit proceeds were utilised for creation of fixed deposits and purchase of immovable assets. The attached assets include land in Indore valued at 6.5 crore, as well as movable properties consisting of bank balances and fixed deposits worth 1.46 crore, all in the names of Ashish Jain and his kin.

  • Related Posts

    Piramal, Ajinomoto team on ADC development and manufacturing

    Piramal Pharma Solutions, a global contract development and manufacturing organization, and Ajinomoto Bio-Pharma Services announced a strategic collaboration to support development and manufacturing of antibody-drug conjugates (ADCs) using AJICAP technology…

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    New Delhi: Aurobindo Pharma Ltd on Friday said it has received final approval from the US health regulator to manufacture and market its generic version of glycerol phenylbutyrate oral liquid…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Piramal, Ajinomoto team on ADC development and manufacturing

    Piramal, Ajinomoto team on ADC development and manufacturing

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Aurobindo Pharma Gets USFDA Nod for Glycerol Liquid

    Cancer cure must not be hostage to Big Pharma

    Cancer cure must not be hostage to Big Pharma

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    GLP-1 drugs emerge as a new option for Indian women bat­tling PCOS

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Aurobindo Pharma gains after receving USFDA nod for Glycerol Phenylbutyrate Oral Liquid

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India

    Legal Loopholes Stall Crackdown On Interstate Fake Drug Rackets In India